Cancer susceptibility and reproductive trade-offs: A model of the evolution of cancer defences

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1673, 2015, Pages

  Boddy, Amy M ^a,b,c   Kokko, Hanna ^c,d   Breden, Felix ^c,e   Wilkinson, Gerald S ^c,f   Athena Aktipis, C ^a,b,c  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Institute for Advanced Study   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e SIMON FRASER UNIVERSITY   (Canada)

^f University of Maryland   (United States)

Author keywords

Cancer defences; Comparative oncology; Life history trade offs; Reproductive competition; Sexual selection

Indexed keywords

BODY SIZE; CANCER; CELLS AND CELL COMPONENTS; COMPARATIVE STUDY; DEFENSE MECHANISM; INTERSPECIFIC COMPETITION; INTRASPECIFIC COMPETITION; LIFE HISTORY THEORY; MORTALITY; PROBABILITY; REPRODUCTIVE STRATEGY; SEX HORMONE; SEXUAL SELECTION; TRADE-OFF;

ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; DISEASE PREDISPOSITION; ECOSYSTEM; EVOLUTION; FEMALE; HUMAN; LONGEVITY; MALE; NEOPLASMS; REPRODUCTION; RISK FACTOR; SEXUAL DEVELOPMENT;

ANIMALS; BIOLOGICAL EVOLUTION; CELL PROLIFERATION; DISEASE SUSCEPTIBILITY; ECOSYSTEM; FEMALE; HUMANS; LONGEVITY; MALE; MODELS, BIOLOGICAL; NEOPLASMS; REPRODUCTION; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84930920223     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0220     Document Type: Article

References (116)

1. Mix MC. 1986 Cancerous diseases in aquatic animals and their association with environmental pollutants: a critical literature review. Mar. Environ. Res. 20, 1–141. (doi:10.1016/0141-1136(86)90013-9).
2. Aktipis CA, Boddy AM, Jansen G, Hibner U, Hochberg ME, Maley CC, Wilkinson GS. 2015 Cancer across the tree of life: cooperation and cheating in multicellularity. Phil. Trans. R. Soc. B 370, 20140219. (doi:10.1098/rstb.2014.0219).
3. Caulin AF, Maley CC. 2011 Peto’s paradox: evolution’s prescription for cancer prevention. Trends Ecol. Evol. 26, 175–182. (doi:10.1016/j.tree.2011.01.002).
4. Leroi AM, Koufopanou V, Burt A. 2003 Cancer selection. Nat. Rev. Cancer 3, 226–231. (doi:10.1038/nrc1016).
5. Williams GC. 1957 Pleiotropy, natural selection, and the evolution of senescence. Evolution 11, 398–411. (doi:10.2307/2406060).
6. Sandland GJ, Minchella DJ. 2003 Costs of immune defense: an enigma wrapped in an environmental cloak? Trends Parasitol. 19, 571–574. (doi:10.1016/j.pt.2003.10.006).
7. Sheldon BC, Verhulst S. 1996 Ecological immunology: costly parasite defences and trade-offs in evolutionary ecology. Trends Ecol. Evol. 11, 317–321. (doi:10.1016/0169-5347(96)10039-2).
8. Crespi BJ, Summers K. 2006 Positive selection in the evolution of cancer. Biol. Rev. 81, 407–424. (doi:10.1017/S1464793106007056).
9. Carter AJ, Nguyen AQ. 2011 Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. BMC Med. Genet. 12, 160. (doi:10.1186/1471-2350-12-160).
10. Leroi AM et al. 2005 What evidence is there for the existence of individual genes with antagonistic pleiotropic effects? Mech. Ageing Dev. 126, 421–429. (doi:10.1016/j.mad.2004.07.012).
11. Kang H-J, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, Rosenwaks Z, Levine AJ, Hu W. 2009 Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl Acad. Sci. USA 106, 9761–9766. (doi:10.1073/pnas.0904280106).
12. Ungewitter E, Scrable H. 2009 Antagonistic pleiotropy and p53. Mech. Ageing Dev. 130, 10–17. (doi:10.1016/j.mad.2008.06.002).
13. Smith KR, Hanson HA, Mineau GP, Buys SS. 2012 Effects of BRCA1 and BRCA2 mutations on female fertility. Proc. R. Soc. B 279, 1389–1395. (doi:10.1098/rspb.2011.1697).
14. Andersson MB. 1994 Sexual selection. Princeton, NJ: Princeton University Press.
15. Rankin DJ, Dieckmann U, Kokko H. 2011 Sexual conflict and the tragedy of the commons. Am. Nat. 177, 780–791. (doi:10.1086/659947).
16. Darwin C. 1871 The descent of man and selection in relation to sex. New York, NY: Appleton.
17. Fernandez AA, Bowser PR. 2010 Selection for a dominant oncogene and large male size as a risk factor for melanoma in the Xiphophorus animal model. Mol. Ecol. 19, 3114–3123. (doi:10.1111/j.1365-294X.2010.04738.x).
18. Fernandez AA, Morris MR. 2008 Mate choice for more melanin as a mechanism to maintain a functional oncogene. Proc. Natl Acad. Sci. USA 105, 13 503–13 507. (doi:10.1073/pnas.0803851105).
19. Gordon M. 1927 The genetics of a viviparous top-minnow Platypoecilus: the inheritance of two kinds of melanophores. Genetics 12, 253–283.
20. Schartl M. 2008 Evolution of Xmrk: an oncogene, but also a speciation gene? Bioessays 30, 822–832. (doi:10.1002/bies.20807).
21. Summers K, Crespi BJ. 2010 Xmrks the spot: life history tradeoffs, sexual selection and the evolutionary ecology of oncogenesis. Mol. Ecol. 19, 3022–3024. (doi:10.1111/j.1365-294X.2010.04739.x).
22. Patton EE, Mathers ME, Schartl M. 2011 Generating and analyzing fish models of melanoma. Methods Cell Biol. 105, 339–366. (doi:10.1016/B978-0-12-381320-6.00014-X).
23. Li C, Zhao H, Liu Z, McMahon C. 2014 Deer antler–a novel model for studying organ regeneration in mammals. Int. J. Biochem. Cell Biol. 56, 111–122. (doi:10.1016/j.biocel.2014.07.007).
24. Suttie J, Fennessy P, Lapwood K, Corson I. 1995 Role of steroids in antler growth of red deer stags. J. Exp. Zool. 271, 120–130. (doi:10.1002/jez.1402710207).
25. Bubenik G, Schams D, Coenen G. 1987 The effect of artificial photoperiodicity and antiandrogen treatment on the antler growth and plasma levels of LH, FSH, testosterone, prolactin and alkaline phosphatase in the male white-tailed deer. Comp. Biochem. Physiol. A, Physiol. 87, 551–559. (doi:10.1016/0300-9629(87)90359-8).
26. Goss R. 1990 Tumor-like growth of antlers in castrated fallow deer: an electron microscopic study. Scann. Microsc. 4, 715–720; discussion 720–711.
27. Suttie JM, Gluckman PD, Butler JH, Fennessy PF, Corson ID, Laas FJ. 1985 Insulin-like growth factor 1 (IGF-1) antler-stimulating hormone? Endocrinology 116, 846–848. (doi:10.1210/endo-116-2-846).
28. Carrasco L, Fierro Y, Sánchez-Castillejo J, Hervas J, Perez J, Gómez-Villamandos J. 1997 Abnormal antler growth associated with testicular hypogonadism in red deer. J. Wildl. Dis. 33, 670–672. (doi:10.7589/0090-3558-33.3.670).
29. Demartini JC, Connolly GE. 1975 Testicular atrophy in Columbian black-tailed deer in California. J. Wildl. Dis. 11, 101–106. (doi:10.7589/0090-3558-11.1.101).
30. Goss RJ. 2012 Deer antlers: regeneration, function and evolution. San Diego, CA: Academic Press.
31. Kierdorf U, Li C, Price JS. 2009 Improbable appendages: deer antler renewal as a unique case of mammalian regeneration. In Seminars in cell and developmental biology, pp. 535–542. Elsevier.
32. Munk B, Garrison E, Clemons B, Keel MK. 2014 Antleroma in a free-ranging white-tailed deer (Odocoileus virginianus). Vet. Pathol. 52, 213–216. (doi:10.1177/0300985814528216).
33. Taylor D, Thomas JW, Marburger R. 1964 Abnormal antler growth associated with hypogonadism in white-tailed deer in Texas. Am. J. Vet. Res. 25, 179–185.
34. Tiller BL, Dagle GE, Cadwell LL. 1997 Testicular atrophy in a mule deer population. J. Wildl. Dis. 33, 420–429. (doi:10.7589/0090-3558-33.3.420).
35. Veeramachaneni DR, Amann RP, Jacobson JP. 2006 Testis and antler dysgenesis in Sitka black-tailed deer on Kodiak Island, Alaska: sequela of environmental endocrine disruption? Environ. Health Perspect. 114, 51–59. (doi:10.1289/ehp.8052).
36. Johnson PA, Giles JR. 2013 The hen as a model of ovarian cancer. Nat. Rev. Cancer 13, 432–436. (doi:10.1038/nrc3535).
37. Fredrickson T. 1987 Ovarian tumors of the hen. Environ. Health Perspect. 73, 35–51. (doi:10.1289/ehp.877335).
38. Stearns SC. 1989 Trade-offs in life-history evolution. Funct. Ecol. 3, 259–268. (doi:10.2307/2389364).
39. Kirkwood TB. 1977 Evolution of ageing. Nature 270, 301–304. (doi:10.1038/270301a0).
40. Campisi J. 2005 Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513–522. (doi:10.1016/j.cell.2005.02.003).
41. Lorenzini A, Stamato T, Sell C. 2011 The disposable soma theory revisited: time as a resource in the theories of aging. Cell Cycle 10, 3853–3856. (doi:10.4161/cc.10.22.18302).
42. Lipman R, Galecki A, Burke DT, Miller RA. 2004 Genetic loci that influence cause of death in a heterogeneous mouse stock. J. Gerontol. A, Biol. Sci. Med. Sci. 59, B977–B983. (doi:10.1093/gerona/59.10.B977).
43. Burek J, Hollander C. 1977 Incidence patterns of spontaneous tumors in BN/Bi rats. J. Natl Cancer Inst. 58, 99–105.
44. Todaro GJ, Green H. 1963 Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299–313. (doi:10.1083/jcb.17.2.299).
45. Fink LS, Roell M, Caiazza E, Lerner C, Stamato T, Hrelia S, Lorenzini A, Sell C. 2011 53BP1 contributes to a robust genomic stability in human fibroblasts. Aging (Albany NY) 3, 836–845.
46. Seluanov A, Hine C, Bozzella M, Hall A, Sasahara TH, Ribeiro AA, Catania KC, Presgraves DC, Gorbunova V. 2008 Distinct tumor suppressor mechanisms evolve in rodent species that differ in size and lifespan. Aging Cell 7, 813–823. (doi:10.1111/j.1474-9726.2008.00431.x).
47. Roche B, Sprouffske K, Hbid H, Misse´ D, Thomas F. 2013 Peto’s paradox revisited: theoretical evolutionary dynamics of cancer in wild populations. Evol. Appl. 6, 109–116. (doi:10.1111/eva.12025).
48. Lorenzini A, Johnson FB, Oliver A, Tresini M, Smith JS, Hdeib M, Sell C, Cristofalo VJ, Stamato TD. 2009 Significant correlation of species longevity with DNA double strand break recognition but not with telomere length. Mech. Ageing Dev. 130, 784–792. (doi:10.1016/j.mad.2009.10.004).
49. DeGregori J. 2011 Evolved tumor suppression: why are we so good at not getting cancer? Cancer Res. 71, 3739–3744. (doi:10.1158/0008-5472.CAN-11-0342).
50. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. 2011 The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol. 12, 259–265. (doi:10.1038/nrm3086).
51. Suh E-K et al. 2006 p63 protects the female germ line during meiotic arrest. Nature 444, 624–628. (doi:10.1038/nature05337).
52. Tomasini R et al. 2008 TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677–2691. (doi:10.1101/gad.1695308).
53. Hu W. 2009 The role of p53 gene family in reproduction. Cold Spring Harb. Perspect. Biol. 1, a001073. (doi:10.1101/cshperspect.a001073).
54. Hanahan D, Weinberg RA. 2000 The hallmarks of cancer. Cell 100, 57–70. (doi:10.1016/S0092-8674(00)81683-9).
55. Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. Cell 144, 646–674. (doi:10.1016/j.cell.2011.02.013).
56. Tutt A, Ashworth A. 2002 The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 8, 571–576. (doi:10.1016/S1471-4914(02)02434-6).
57. Chen S, Parmigiani G. 2007 Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25, 1329–1333. (doi:10.1200/JCO.2006.09.1066).
58. Liu C-Y, Flesken-Nikitin A, Li S, Zeng Y, Lee W-H. 1996 Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835–1843. (doi:10.1101/gad.10.14.1835).
59. Messager S et al. 2005 Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc. Natl Acad. Sci. USA 102, 1761–1766. (doi:10.1073/pnas.0409330102).
60. Skorupskaite K, George JT, Anderson RA. 2014 The kisspeptin-GnRH pathway in human reproductive health and disease. Hum. Reprod. Update 20, 485–500. (doi:10.1093/humupd/dmu009).
61. Lee J-H, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. 1996 KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl Cancer Inst. 88, 1731–1737. (doi:10.1093/jnci/88.23.1731).
62. Hiden U, Bilban M, Knöfler M, Desoye G. 2007 Kisspeptins and the placenta: regulation of trophoblast invasion. Rev. Endocr. Metab. Disord. 8, 31–39. (doi:10.1007/s11154-007-9030-8).
63. Cartwright JE, Williams PJ. 2012 Altered placental expression of kisspeptin and its receptor in preeclampsia. J. Endocrinol. 214, 79–85. (doi:10.1530/JOE-12-0091).
64. Stearns SC. 2012 Evolutionary medicine: its scope, interest and potential. Proc. R. Soc. B 279, 4305–4321. (doi:10.1098/rspb.2012.1326).
65. D’Souza AW, Wagner GP. 2014 Malignant cancer and invasive placentation A case for positive pleiotropy between endometrial and malignancy phenotypes. Evol. Med. Public Health 2014, 136–145. (doi:10.1093/emph/eou022).
66. Wildman DE, Chen C, Erez O, Grossman LI, Goodman M, Romero R. 2006 Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc. Natl Acad. Sci. USA 103, 3203–3208. (doi:10.1073/pnas.0511344103).
67. Braude S, Tang-Martinez Z, Taylor GT. 1999 Stress, testosterone, and the immunoredistribution hypothesis. Behav. Ecol. 10, 345–350. (doi:10.1093/beheco/10.3.345).
68. Dribe M. 2004 Long-term effects of childbearing on mortality: evidence from pre-industrial Sweden. Popul. Stud. 58, 297–310. (doi:10.1080/0032472042000272357).
69. Lycett JE, Dunbar R, Voland E. 2000 Longevity and the costs of reproduction in a historical human population. Proc. R. Soc. Lond. B 267, 31–35. (doi:10.1098/rspb.2000.0962).
70. Jasienska G. 2009 Reproduction and lifespan: tradeoffs, overall energy budgets, intergenerational costs, and costs neglected by research. Am. J. Hum. Biol. 21, 524–532. (doi:10.1002/ajhb.20931).
71. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebæk NE. 1995 Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J. Clin. Endocrinol. Metab. 80, 2534–2542. (doi:10.1210/jc.80.8.2534).
72. Butler AA, Roith DL. 2001 Control of growth by the somatropic axis: growth hormone and the insulinlike growth factors have related and independent roles. Annu. Rev. Physiol. 63, 141–164. (doi:10.1146/annurev.physiol.63.1.141).
73. Moschos SJ, Mantzoros CS. 2001 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317–332. (doi:10.1159/000066230).
74. Emlen DJ, Warren IA, Johns A, Dworkin I, Lavine LC. 2012 A mechanism of extreme growth and reliable signaling in sexually selected ornaments and weapons. Science 337, 860–864. (doi:10.1126/science.1224286).
75. Chaves J, Saif MW. 2011 IGF system in cancer: from bench to clinic. Anti-cancer Drugs 22, 206–212. (doi:10.1097/CAD.0b013e32834258a1).
76. Renehan AG, Zwahlen M, Minder C, O’Dwyer S, Shalet SM, Egger M. 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363, 1346–1353. (doi:10.1016/S0140-6736(04)16044-3).
77. Milman S, Atzmon G, Huffman DM, Wan J, Crandall JP, Cohen P, Barzilai N. 2014 Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 13, 769–771. (doi:10.1111/acel.12213).
78. Anisimov VN, Bartke A. 2013 The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer. Crit. Rev. Oncol. Hematol. 87, 201–223. (doi:10.1016/j.critrevonc.2013.01.005).
79. Guevara-Aguirre J et al. 2011 Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 3, 70ra13. (doi:10.1126/scitranslmed.3001845).
80. Group EH.BC.C. 2003 Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl Cancer Inst. 95, 1218–1226. (doi:10.1093/jnci/djg022).
81. Holly J, Gunnell D, Smith GD. 1999 Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J. Endocrinol. 162, 321–330. (doi:10.1677/joe.0.1620321).
82. Hyde Z, Flicker L, McCaul KA, Almeida OP, Hankey GJ, Chubb SP, Yeap BB. 2012 Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol. Biomark. Prev. 21, 1319–1329. (doi:10.1158/1055-9965.EPI-12-0129).
83. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578. (doi:10.1016/S0140-6736(08)60269-X).
84. Stingl J. 2011 Estrogen and progesterone in normal mammary gland development and in cancer. Horm. Cancer 2, 85–90. (doi:10.1007/s12672-010-0055-1).
85. Summers K, Crespi B. 2008 The androgen receptor and prostate cancer: a role for sexual selection and sexual conflict? Med. Hypotheses 70, 435–443. (doi:10.1016/j.mehy.2007.04.044).
86. Trivers R. 1972 Parental investment and sexual selection. In Sexual selection and the descent of man 1871–1971 (ed. BG Campbell), pp. 136–179. Chicago, IL: Aldine.
87. Dorak MT, Karpuzoglu E. 2012 Gender differences in cancer susceptibility: an inadequately addressed issue. Front. Genet. 3, 268. (doi:10.3389/fgene.2012.00268).
88. Syed DN, Mukhtar H. 2012 Gender bias in skin cancer: role of catalase revealed. J. Invest. Dermatol. 132, 512–514. (doi:10.1038/jid.2011.423).
89. Pawlowski B, Dunbar R, Lipowicz A. 2000 Evolutionary fitness: tall men have more reproductive success. Nature 403, 156. (doi:10.1038/35003107).
90. Nettle D. 2002 Height and reproductive success in a cohort of British men. Hum. Nat. 13, 473–491. (doi:10.1007/s12110-002-1004-7).
91. Mueller U, Mazur A. 2001 Evidence of unconstrained directional selection for male tallness. Behav. Ecol. Sociobiol. 50, 302–311. (doi:10.1007/s002650100370).
92. Shors AR, Solomon C, McTiernan A, White E. 2001 Melanoma risk in relation to height, weight, and exercise (United States). Cancer Causes Control 12, 599–606. (doi:10.1023/A:1011211615524).
93. Rasmussen F, Gunnell D, Ekbom A, Hallqvist J, Tynelius P. 2003 Birth weight, adult height, and testicular cancer: cohort study of 337,249 Swedish young men. Cancer Causes Control 14, 595–598. (doi:10.1023/A:1024860826830).
94. Giles GG, Severi G, English DR, McCredie MR, MacInnis R, Boyle P, Hopper JL. 2003 Early growth, adult body size and prostate cancer risk. Int. J. Cancer 103, 241–245. (doi:10.1002/ijc.10810).
95. Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TI. 2004 Growth patterns and the risk of breast cancer in women. N. Engl. J. Med. 351, 1619–1626. (doi:10.1056/NEJMoa040576).
96. Robson H, Siebler T, Shalet SM, Williams GR. 2002 Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr. Res. 52, 137–147. (doi:10.1203/00006450-200208000-00003).
97. Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. 2003 Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J. Gerontol. A, Biol. Sci. Med. Sci. 58, B291–B296. (doi:10.1093/gerona/58.4.B291).
98. Archer J. 2006 Testosterone and human aggression: an evaluation of the challenge hypothesis. Neurosci. Biobehav. Rev. 30, 319–345. (doi:10.1016/j.neubiorev.2004.12.007).
99. Gettler LT, McDade TW, Feranil AB, Kuzawa CW. 2011 Longitudinal evidence that fatherhood decreases testosterone in human males. Proc. Natl Acad. Sci. USA 108, 16 194–16 199. (doi:10.1073/pnas.1105403108).
100. Peters M, Simmons LW, Rhodes G. 2008 Testosterone is associated with mating success but not attractiveness or masculinity in human males. Anim. Behav. 76, 297–303. (doi:10.1016/j.anbehav.2008.02.008).
101. Alvarado LC. 2013 Do evolutionary life-history trade-offs influence prostate cancer risk? A review of population variation in testosterone levels and prostate cancer disparities. Evol. Appl. 6, 117–133. (doi:10.1111/eva.12036).
102. Vermeulen A, Rubens R, Verdonck L. 1972 Testosterone secretion and metabolism in male senescence. J. Clin. Endocrinol. Metab. 34, 730–735. (doi:10.1210/jcem-34-4-730).
103. Wang R-S, Yeh S, Tzeng C-R, Chang C. 2009 Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr. Rev. 30, 119–132. (doi:10.1210/er.2008-0025).
104. Heinlein CA, Chang C. 2004 Androgen receptor in prostate cancer. Endocr. Rev. 25, 276–308. (doi:10.1210/er.2002-0032).
105. Del Giudice M, Ellis BJ, Shirtcliff EA. 2011 The adaptive calibration model of stress responsivity. Neurosci. Biobehav. Rev. 35, 1562–1592. (doi:10.1016/j.neubiorev.2010.11.007).
106. Trumble BC, Cummings D, von Rueden C, O’Connor KA, Smith EA, Gurven M, Kaplan H. 2012 Physical competition increases testosterone among Amazonian forager-horticulturalists: a test of the ‘challenge hypothesis’. Proc. R. Soc. B 279, 2907–2912. (doi:10.1098/rspb.2012.0455).
107. Trumble BC, Brindle E, Kupsik M, O’Connor KA. 2010 Responsiveness of the reproductive axis to a single missed eveningmeal in young adult males. Am. J. Hum. Biol. 22, 775–781. (doi:10.1002/ajhb.21079).
108. Henss R. 2000 Waist-to-hip ratio and female attractiveness. Evidence from photographic stimuli and methodological considerations. Pers. Ind. Differences 28, 501–513. (doi:10.1016/S0191-8869(99)00115-4).
109. Jasienska G, Lipson SF, Ellison PT, Thune I, Ziomkiewicz A. 2006 Symmetrical women have higher potential fertility. Evol. Hum. Behav. 27, 390–400. (doi:10.1016/j.evolhumbehav.2006.01.001).
110. Singh D. 1993 Body shape and women’s attractiveness. Hum. Nat. 4, 297–321. (doi:10.1007/BF02692203).
111. Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P. 2009 Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod. Biol. Endocrinol. 7, 4330–4337. (doi:10.1186/1477-7827-7-40).
112. Aktipis CA, Ellis BJ, Nishimura KK, Hiatt RA. 2014 Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility. Evol. Med. Public Health B 1, 52–74. (doi:10.1093/emph/eou028).
113. Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, DiCioccio R, Felberg A, West DW. 2004 Prevalence of BRCA1 mutation carriers among US non-Hispanic Whites. Cancer Epidemiol. Biomark. Prev. 13, 2078–2083.
114. Kim JS et al. 2013 The relationship between preeclampsia, pregnancy-induced hypertension and maternal risk of breast cancer: a meta-analysis. Acta Oncologica (Stockholm, Sweden) 52, 1643–1648. (doi:10.3109/0284186x.2012.750033).
115. Vatten L, Romundstad P, Trichopoulos D, Skjaerven R. 2002 Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br. J. Cancer 87, 971–973. (doi:10.1038/sj.bjc.6600581).
116. Calderon-Margalit R, Friedlander Y, Yanetz R, Deutsch L, Perrin MC, Kleinhaus K, Tiram E, Harlap S, Paltiel O. 2009 Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. Am. J. Obstet. Gynecol. 200, e61–e68. (doi:10.1016/j.ajog.2008.06.057).